Core C - Biomarker and Biobanking Core

核心 C - 生物标志物和生物样本库核心

• 批准号: 10627331
• 负责人: Michele Michele Ramsay
• 金额: $ 49.3万
• 依托单位: HARVARD SCHOOL OF PUBLIC HEALTH
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-15 至 2028-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10627331
• 关键词: African; Aging; Amyloid beta-Protein; Artificial Intelligence; Bioinformatics; Biological; Biological Markers; Biological Process; Biological Sciences; Biometry; Blood; Blood Glucose; Blood Pressure; Blood capillaries; Body Composition; Brain natriuretic peptide; Cardiac; Cardiometabolic Disease; Categories; Characteristics; Collaborations; Collection; Communities; Computer software; DNA; Data; Data Analyses; Dementia; Dryness; Echocardiography; Electrocardiogram; Ensure; Epidemiology; Epigenetic Process; Evaluation; Genomics; Genotype; Glial Fibrillary Acidic Protein; HIV; Health; Health Transition; Heart failure; Image; Inflammation; Infrastructure; International; Laboratories; Length; Light; Longitudinal Studies; Magnetic Resonance Imaging; Measurement; Measures; Medical Research; Methylation; Molecular; Morbidity - disease rate; Participant; Pathogenicity; Phenotype; Physiological; Plasma; Population; Procedures; Process; Public Health; Quality Control; Reporting; Research; Research Project Grants; Resources; Rural; Sampling; Sodium; South Africa; Spottings; Surveys; System; Test Result; Therapeutic Intervention; Time; Training; Troponin I; Trust; United States National Institutes of Health; Universities; Urine; Venous; Wit; biobank; clinically relevant; cognitive function; cohort; comparative; dementia risk; disorder risk; genetic association; genomic data; handheld mobile device; health application; improved; indexing; interest; mortality; neurofilament; neuroimaging; novel; novel marker; pharmacologic; point of care; programs; radiological imaging; response; risk stratification; sample collection; specific biomarkers; tau-1; telomere

Core C: Biomarker and Biobanking Core—Abstract The Biomarker and Biobanking Core will provide scientific direction and oversight of biomarker and biobanking samples for the entire Health, Aging and Dementia in South Africa: A Longitudinal Study (HAALSI) Program. The Core is led by two Co-PIs who will oversee a group of international experts in the fields of epidemiology, genomics, bioinformatics, epigenetics, biostatistics, and biomarker analysis. A biomarker is defined by NIH as a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. We further divide biomarkers into two broad categories for the purpose of Core C: (1) those that do not require a biological sample to be collected and/or stored (e.g., imaging, blood pressure); and (2) those that require a biological sample to be further analyzed, whether at the point of care (e.g., blood glucose) or in a laboratory (e.g., urine sodium, DNA).This Core will allow us to continue our commitment to longitudinal sample collection in Agincourt and the coordinated use of biomarkers across all four research projects. The proposed HAALSI National survey will augment the HAALSI Agincourt community study with biomarker data from a nationally representative cohort. The growing collection of baseline and new biomarker data related to dementia, cognitive function, cardiometabolic diseases, HIV, and inflammation will inform many research questions and provide opportunities for comparative data for analyses. In particular, we are collecting and analyzing novel biomarkers for dementia and heart failure that have not been measured extensively in African populations. Neuroimaging and plasma samples for amyloid beta (Aβ), phosphorylated tau (p-tau), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) will allow for improved phenotyping and relationships between risk factors for dementia. Further, novel cardiac biomarkers of echocardiography and plasma levels of NT-pro brain natriuretic peptide (BNP), cardiac troponin I, and Galactin-3 will be measured for longitudinal evaluation for the first time in an African cohort, allowing for improved phenotyping and risk stratification for cardiometabolic disease morbidity and mortality.

核心C：生物标志物和生物库核心摘要 生物标志物和生物库核心将为生物标志物和生物库提供科学指导和监督 南非健康，老龄化和痴呆症的样本：纵向研究（HAALSI） 程序.核心小组由两名共同首席执行官领导，他们将监督一个国际专家小组， 流行病学、基因组学、生物信息学、表观遗传学、生物统计学和生物标志物分析。生物标志物是 NIH将其定义为一种客观测量和评估为正常指标的特征， 生物过程、致病过程或对治疗干预的药理学反应。我们 为了核心C的目的，进一步将生物标志物分为两大类：（1）那些不需要 待收集和/或储存的生物样品（例如，（2）血压;（3）血压;（4）血压。 待进一步分析的生物样品，无论是在护理点（例如，血糖）或在实验室中 (e.g.,尿钠，DNA）。该核心将使我们能够继续致力于纵向样本采集 以及在所有四个研究项目中协调使用生物标志物。建议的HAALSI 国家调查将利用来自全国的生物标志物数据来加强HAALSI Agincourt社区研究 代表性的队列。越来越多的与痴呆症相关的基线和新生物标志物数据的收集， 认知功能、心脏代谢疾病、艾滋病毒和炎症将为许多研究问题提供信息， 为分析提供比较数据。特别是，我们正在收集和分析小说 痴呆症和心力衰竭的生物标志物尚未在非洲人群中广泛测量。 β淀粉样蛋白（Aβ）、磷酸化tau蛋白（p-tau）、神经丝轻链的神经成像和血浆样本 (NfL)和胶质细胞酸性蛋白（GFAP）将允许改善表型和之间的关系， 痴呆症的危险因素此外，超声心动图和血浆NT-pro水平的新心脏生物标志物 将测量脑钠肽（BNP）、心肌肌钙蛋白I和半乳糖凝集素-3进行纵向评价 首次在非洲队列中，允许改善表型和风险分层， 心脏代谢疾病发病率和死亡率。